We extend a warm invitation to experts and researchers worldwide to join us at the "G20 Global Pharma Summit Series-France," Will be held in France on November 13-14, 2023.
G20 Global Pharma Summit acts as a forum for discussions and cooperation on diverse facets of the pharmaceutical sector, with the overarching goals of promoting innovation, enhancing medicine accessibility, and advancing global health security. The conference serves as a valuable platform for exchanging perspectives, sharing best practices, and devising solutions to address the industry's pressing challenges.
It will likewise give the opportunity to stay in contact with different members for laying out any new future coordinated efforts. The theme of the meeting is " "Empowering Innovation and Transforming Healthcare: Pioneering Advances in Pharma"
The G20 Global Pharma Summit will provide a comprehensive overview of the latest developments, emerging strategies, and future directions in the field of pharma and pharmaceutics. It will cover various essential processes such as target identification and validation and optimization. Additionally, the conference will delve into important aspects of pharma development, including the optimization of chemical synthesis and formulation, as well as the evaluation of toxicological and adverse effects.
The G20 Global Pharma Summit Series-France will cover a diverse range of topics including Pharmacology, Pharmaceutical Microbiology, Pharmaceutical Biotechnology, Biopharmaceuticals, Nanotechnology in Pharmaceutics, Drug Development, Pharmaceutical Analysis and Quality Assurance, Neuropharmacology, Pharmacokinetics, Pharmaceutical Research and Development, Pharmaceutical Industry, Pharma Industry Analysis, Drug Delivery Systems, Digital Pharma, Novel Drug Delivery Systems, Pharmaceutical Chemistry, and Pharmaceutical Manufacturing.
The G20 Global Pharma Summit Series-France also intends to provide its attendees with engaging feature addresses, corresponding banner and oral presentation, eye - catching exhibits, expensive sponsorship opportunities, and media coordinated efforts and affiliations.